136 related articles for article (PubMed ID: 23482770)
1. Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer.
Gottschling S; Jensen K; Herth FJ; Thomas M; Schnabel PA; Herpel E
Anticancer Res; 2013 Mar; 33(3):981-90. PubMed ID: 23482770
[TBL] [Abstract][Full Text] [Related]
2. The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.
Herpel E; Jensen K; Muley T; Warth A; Schnabel PA; Meister M; Herth FJ; Dienemann H; Thomas M; Gottschling S
Anticancer Res; 2011 Dec; 31(12):4491-500. PubMed ID: 22199321
[TBL] [Abstract][Full Text] [Related]
3. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Li F; Zeng H; Ying K
Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756
[TBL] [Abstract][Full Text] [Related]
4. Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis.
Gottschling S; Jensen K; Warth A; Herth FJ; Thomas M; Schnabel PA; Herpel E
Eur Respir J; 2013 Mar; 41(3):656-63. PubMed ID: 22743677
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
[TBL] [Abstract][Full Text] [Related]
6. Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors.
Kumamoto H; Ohki K
J Oral Pathol Med; 2010 Jan; 39(1):87-93. PubMed ID: 19659474
[TBL] [Abstract][Full Text] [Related]
7. CD133 expression: a potential prognostic marker for non-small cell lung cancers.
Mizugaki H; Sakakibara-Konishi J; Kikuchi J; Moriya J; Hatanaka KC; Kikuchi E; Kinoshita I; Oizumi S; Dosaka-Akita H; Matsuno Y; Nishimura M
Int J Clin Oncol; 2014 Apr; 19(2):254-9. PubMed ID: 23479121
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.
Alamgeer M; Ganju V; Szczepny A; Russell PA; Prodanovic Z; Kumar B; Wainer Z; Brown T; Schneider-Kolsky M; Conron M; Wright G; Watkins DN
Thorax; 2013 Dec; 68(12):1095-104. PubMed ID: 23878161
[TBL] [Abstract][Full Text] [Related]
9. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
13. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
14. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
Qiu ZX; Zhao S; Mo XM; Li WM
Int J Clin Exp Pathol; 2015; 8(6):6589-95. PubMed ID: 26261540
[TBL] [Abstract][Full Text] [Related]
16. Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.
Sterlacci W; Savic S; Fiegl M; Obermann E; Tzankov A
J Thorac Oncol; 2014 Jan; 9(1):41-9. PubMed ID: 24346092
[TBL] [Abstract][Full Text] [Related]
17. Monitoring microRNAs using a molecular beacon in CD133+/ CD338+ human lung adenocarcinoma-initiating A549 cells.
Yao Q; Sun JG; Ma H; Zhang AM; Lin S; Zhu CH; Zhang T; Chen ZT
Asian Pac J Cancer Prev; 2014; 15(1):161-6. PubMed ID: 24528019
[TBL] [Abstract][Full Text] [Related]
18. The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Gottschling S; Herpel E; Eberhardt WE; Heigener DF; Fischer JR; Köhne CH; Kortsik C; Kuhnt T; Muley T; Meister M; Bischoff HG; Klein P; Moldenhauer I; Schnabel PA; Thomas M; Penzel R
Lung Cancer; 2012 Jul; 77(1):183-91. PubMed ID: 22483783
[TBL] [Abstract][Full Text] [Related]
19. Cancer Stem Cell Markers in Eyelid Sebaceous Gland Carcinoma: High Expression of ALDH1, CD133, and ABCG2 Correlates With Poor Prognosis.
Kim N; Choung HK; Lee MJ; Khwarg SI; Kim JE
Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1813-9. PubMed ID: 25711631
[TBL] [Abstract][Full Text] [Related]
20. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
